The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
Open accessAbstract
CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution and infections for patients remaining in remission after axi-cel for LBCL. Prolonged cytopenias (those occurring at or after day 30 following infusion) were common with >= grade 3 neutropenia seen in 21/70 (30-0%) patients at day 30 and persisting in 3/31 (9-7%) patients at 1 year. B cells were undetectable in 30/34 (88-2%) patients at day 30, but were detected in 11/19 (57-9%) at 1 year. Median IgG levels reached a nadir at day 180. By contrast, CD4 T cells decreased from baseline and were persistently low with a median CD4 count of 155 cells/μl at 1 year after axi-cel (n=19, range 33 – 269). In total, 23/85 (27-1%) patients received IVIG after axi-cel, and 34/85 (40-0%) received G-CSF. Infections in the first 30 days occurred in 31/85 (36-5%) patients, of which 11/85 (12-9%) required intravenous antibiotics or hospitalization (“severe”) and were associated with cytokine release syndrome (CRS), neurotoxicity, tocilizumab use, corticosteroid use, and bridging therapy on univariate analyses. After day 30, 7 severe infections occurred, with no late deaths due to infection. Prolonged cytopenias are common following axi-cel therapy for LBCL and typically recover with time. Most patients experience profound and prolonged CD4 T cell immunosuppression without severe infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Self-citationLocke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationChimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chavez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Bot, A., Rossi, J. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.020 · Cited by 620
Self-citationInfectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Hill, J. A., Li, D., Hay, K. A., Green, M. L., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., Boeckh, M., & Turtle, C. J. (2018) · Blood · doi:10.1182/blood-2017-07-793760 · Cited by 576
Early and late hematologic toxicity following CD19 CAR-T cells
Fried, S., Avigdor, A., Bielorai, B., Meir, A., Besser, M. J., Schachter, J., Shimoni, A., Nagler, A., Toren, A., & Jacoby, E. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0487-3 · Cited by 401
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Yang, J. C., Sherry, R. M., Feldman, S. A., McIntyre, L., Bot, A., Rossi, J., Lam, N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.004 · Cited by 284
Park, J. H., Romero, F. A., Taur, Y., Sadelain, M., Brentjens, R. J., Hohl, T. M., & Seo, S. K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy152 · Cited by 276
Cited by
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou-el-Enein, M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 554
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Schubert, M.-L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Müller-Tidow, C., & Dreger, P. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 491
Rejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Frölich, L., Ackermann, J., Bücklein, V., et al. (2021) · Blood · doi:10.1182/blood.2020010543 · Cited by 475
Self-citationSurvival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301665 · Cited by 455
Self-citation
Metadata
- Authors
- Logue, J. M., Zucchetti, E., Bachmeier, C. A., Krivenko, G. S., Larson, V., Ninh, D., Grillo, G., Cao, B., Kim, J., Chavez, J. C., Baluch, A., Khimani, F., Lazaryan, A., Nishihori, T., Liu, H. D., Pinilla-Ibarz, J., Shah, B. D., Faramand, R., Coghill, A. E., Davila, M. L., Dholaria, B. R., Jain, M. D., & Locke, F. L.
- Venue
- Haematologica
- Published
- 2020-04-23
- Volume
- 106
- Issue
- 4
- Pages
- 978-986
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W3017589029
- Cited by
- 271
- References
- 18
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. https://app.cochat.ai/papers/10.3324/haematol.2019.238634
- The paper
- Logue, J. M., Zucchetti, E., Bachmeier, C. A., Krivenko, G. S., Larson, V., Ninh, D., Grillo, G., Cao, B., Kim, J., Chavez, J. C., Baluch, A., Khimani, F., Lazaryan, A., Nishihori, T., Liu, H. D., Pinilla-Ibarz, J., Shah, B. D., Faramand, R., Coghill, A. E., . . . Locke, F. L. (2020). Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. https://doi.org/10.3324/haematol.2019.238634
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.